{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Monk BJ"],"funding":["NCI NIH HHS"],"pagination":["981-992"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11934258"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(11)"],"pubmed_abstract":["Background
The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.Patients and methods
Patients were randomized 2:1 to niraparib or placebo, stratified by response to first-line treatment, receipt of neoadjuvant chemotherapy, and tumor HRD status. After reaching 60% target maturity, OS was evaluated via a stratified log-rank test using randomization stratification factors and summarized using Kaplan-Meier methodology. OS testing was hierarchic"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial."],"pmcid":["PMC11934258"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Heitz F","Vulsteke C","Perez MJR","Gaba L","Bruchim I","Barretina-Ginesta MP","O'Malley DM","Moore RG","Mirza MR","Bradley WH","Pisano C","Monk BJ","Shtessel L","Redondo A","Haslund CA","Chase DM","Malinowska IA","Lorusso D","Holman LL","Vergote I","DiSilvestro P","O'Cearbhaill RE","Pothuri B","McCormick CC","Herzog TJ","Graybill W","Gonzalez-Martin A","Compton N","Shahin MS","Freyer G"],"additional_accession":[]},"is_claimable":false,"name":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.","description":"Background
The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.Patients and methods
Patients were randomized 2:1 to niraparib or placebo, stratified by response to first-line treatment, receipt of neoadjuvant chemotherapy, and tumor HRD status. After reaching 60% target maturity, OS was evaluated via a stratified log-rank test using randomization stratification factors and summarized using Kaplan-Meier methodology. OS testing was hierarchic","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-05T09:24:16.664Z","creation":"2026-05-15T03:13:01.386Z"},"accession":"S-EPMC11934258","cross_references":{"pubmed":["39284381"],"doi":["10.1016/j.annonc.2024.08.2241"]}}